You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab

Alerts

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address